Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

BD Veritor™ SARS-CoV-2 Control Swabs

10 SARS-CoV-2 positive and 10 SARS-CoV-2 negative quality control swabs

Supplier:  BD Veritor™ 256087

Catalog No. B256087


Explore available promotions
Add to Cart

Description

Description

  • To be used with BD Veritor™ System
  • For Rapid Detection of SARS-CoV-2 (256082)
TRUSTED_SUSTAINABILITY
Specifications

Specifications

SARS-CoV-2
BD Veritor System for Rapid Detection of SARS-CoV-2 (256082)
Control Swab
10 Paired Positive/Negative Control Swabs
Nasal Swab
Safety and Handling

Safety and Handling

ShelfLife : Max 18 months

SDS
Documents

Documents

Product Certifications
Promotions

Promotions

Product Content Correction

Your input is important to us. Please complete this form to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

*The BD Veritor™ Plus System for Rapid Detection of SARS-CoV-2 is intended for the qualitative detection of SARS-CoV-2 nucleocapsid antigens in direct anterior nasal swabs from individuals who are either suspected of COVID-19 by their health care provider within the first five days of the onset of symptoms, or from individuals without symptoms or other epidemiological reasons to suspect COVID-19 when tested twice over two or three days with at least 24 hours and no more than 48 hours between tests.

  • This product has not been FDA cleared or approved; but has been authorized by FDA under an EUA for use by authorized laboratories.
  • This product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens.
  • This product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.